Thinly traded Castle Biosciences (CSTL +1.7%) is up, albeit on a modest 19K shares, on the heels of its Q4 update. Highlights:
DecisionDx-Melanoma test reports up 37% to 3,270.
DecisionDx-UM test reports up 13% to 434.
Second commercial expansion executed last month, doubling of personnel.
Cash and equivalents at year-end: ~$99M.
H2 2020: Launch DecisionDx-SCC gene expression profile (GEP) test for high-risk cutaneous squamous cell carcinoma. Announce data from studies of GEP test for patients with suspicious pigmented lesions.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.